Biohit OyjLTS:0DRP -5.09%78 EBIT per Share is €0.20 as of Dec. 2025. GuruFocus rates LTS:0DRP with a GF Score™ of 78/100 and a GF Value™ of €2.70 (Fairly Valued). The stock has 3 warning signs investors should review. Among 687 Medical Devices & Instruments companies, Biohit Oyj ranks better than 84.43% on this metric.
Biohit Oyj's EBIT per Share for the
six
months ended in Dec. 2025 was €0.12.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.20.
During the past 12 months, the average EBIT per Share Growth Rate of Biohit Oyj was 24.40% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 40.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Biohit Oyj's EBIT per Share or its related term are showing as below:
LTS:0DRP'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -24.6 Med: 18.5 Max: 40.7
Current: 40.7
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Biohit Oyj was 40.70% per year. The lowest was -24.60% per year. And the median was 18.50% per year.
LTS:0DRP's 3-Year EBIT Growth Rate is ranked better than 84.43% of 687
companies
in the Medical Devices & Instruments industry
Industry Median: 9.4
vs LTS:0DRP: 40.70
Biohit Oyj's EBIT for the
six
months ended in Dec. 2025 was €1.80 Mil.
Biohit Oyj (LTS:0DRP) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Biohit Oyj EBIT per Share Related Terms
Biohit Oyj EBIT per Share Historical Data
* Premium members only.
The historical data trend for Biohit Oyj's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.20
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biohit Oyj (LTS:0DRP) has a EBIT per Share of €0.20 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Biohit Oyj and its competitors. According to the industry distribution chart, Biohit Oyj ranks #107 out of 687 companies in the Medical Devices & Instruments industry, placing it in the top 15.6%.
Is Biohit Oyj's EBIT per Share too high?
Biohit Oyj's current EBIT per Share is €0.20. Based on the distribution chart, Biohit Oyj ranks #107 out of 687 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Biohit Oyj has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biohit Oyj's EBIT per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Biohit Oyj ranks #107 out of 687 companies for EBIT per Share. This places Biohit Oyj in the top 16% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 9.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.40, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Biohit Oyj and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biohit Oyj's current EBIT per Share is €0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biohit Oyj stock overvalued right now?
Based on GuruFocus' analysis, Biohit Oyj (LTS:0DRP) is currently considered Fairly Valued. The stock's GF Value™ is €2.70, compared to a current price of €2.71 — trading 0.2% above its estimated fair value. The current EBIT per Share is €0.20. Biohit Oyj's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Biohit Oyj (LTS:0DRP), the current EBIT per Share is €0.20 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biohit Oyj (LTS:0DRP) Overvalued in 2026?
Based on GuruFocus' analysis, Biohit Oyj stock appears to be overvalued.
The current stock price of €2.71 is trading 0.2% above its estimated GF Value™ of €2.70.
GuruFocus considers Biohit Oyj to be Fairly Valued.
Key valuation signals for LTS:0DRP:
EBIT per Share: €0.20
GF Value™: €2.70 vs. price of €2.71 (0.2% above fair value)
No single metric tells the full story. See the LTS:0DRP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biohit Oyj is a globally operating Finnish biotechnology company that develops diagnostic and other health products. Its products include GastroPanel quick test assesses the structure and function of the stomach lining; ColonView quick test is an immunochemical fecal occult blood test (FIT) developed; Acetium capsules protect the stomach lining from carcinogenic acetaldehyde, especially in people with acid-free stomachs. The company's product portfolio consists of diagnostic tests, analysis systems, products binding carcinogenic acetaldehyde into a harmless compound and monoclonal antibodies.
78GF Score
Get the complete analysis for LTS:0DRP
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0DRP has been successfully added to your 
